Preclinical Safety Assessment of the HB-ATV-8 Intranasal Vaccine Designed to Control Atherosclerosis and Metabolic-Associated Fatty Liver Disease.
Calixto-Tlacomulco, S. D., Luna-Reyes, I., Villa-Jaimes, G. S., Montalván-Sorrosa, D., Gutiérrez-Vidal, R. G., Pérez-Hernández, E. G., Picones, A., Durán-Pastén, M. L., Lara-Figueroa, C. O., Hernández-Cruz, A., Avendaño-Estrada, A., Ávila-Rodríguez, M. Á., Reyes-Grajeda, J. P., & Mas-Oliva, J. (2026). Preclinical Safety Assessment of the HB-ATV-8 Intranasal Vaccine Designed to Control Atherosclerosis and Metabolic-Associated Fatty Liver Disease. Archives of Medical Research, 57(6), 103429. https://doi.org/10.1016/j.arcmed.2026.103429
The intranasal vaccine HB-ATV-8 contains the Seq-1 peptide (CHLLVDFLQSLS) as the active component within a nanoparticle formulation. It targets the cholesterol ester transfer protein (CETP) by inducing the formation of specific autoantibodies and a cellular antifibrotic response. It has demonstrated efficacy in preventing atherogenesis, liver steatosis, and fibrosis in preclinical models. Given that previously synthesized CETP inhibitors have been associated with increased cardiovascular risk, a preclinical safety assessment of HB-ATV-8 was conducted.